The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10447 malaria professionals are enjoying the free benefits of MalariaWorld today

artemether-lumefantrine

Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance/resistance in Maputo before and after the implementation of artemisinin-based combination therapy

August 13, 2014 - 16:39 -- Open Access
Author(s): 
Lobo E, de Sousa B, Rosa S, Figueiredo P, Lobo L, Pateira S, Fernandes N, Nogueira F
Reference: 
Malaria Journal 2014, 13 :300 (6 August 2014)

The prevalence of pfmdr1 different alleles in Maputo and Mozambique is not known, either after or before the introduction of ACT. Pfmdr1 molecular markers related to Plasmodium falciparum susceptibility were analysed before and after transition to ACT.

Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia

July 3, 2014 - 11:54 -- Open Access
Author(s): 
Kebede S, Medhin G, Berhe N, Teklehaymanot T, Gebru T, Clause R, Velavan TP, Aseffa A
Reference: 
Malaria Journal 2014, 13 :244 (25 June 2014)

The study reports for the first time the return of chloroquine sensitive P. falciparum in Ethiopia.

Medical Treatment: 

Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling

April 16, 2014 - 19:05 -- Open Access
Author(s): 
Hodel EM, Kay K, Hayes DJ, Terlouw DJ, Hastings IM
Reference: 
Malaria Journal 2014, 13 :138 (7 April 2014)

The model highlights the sub-optimally low ratio of DHA:PPQ which, in combination with the narrow therapeutic dose range of PPQ compared to DHA that drives the weight or age cut-offs, leaves DHA at a high risk of under-dosing.

Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem(R)) for bioequivalence in a randomized, open-label, two-period study

September 9, 2013 - 15:26 -- Open Access
Author(s): 
Lefèvre G, Bhad P, Jain J, Kalluri S, Cheng Y, Dave H, Stein DS
Reference: 
Malaria Journal 2013, 12:312 (8 September 2013)
MalariaWorld

These novel formulations are easy to administer and may improve adherence in the treatment of uncomplicated malaria caused by Plasmodium falciparum.

Medical Condition: 

Improving Pharmacokinetic-Pharmacodynamic Modeling to Investigate Anti-Infective Chemotherapy with Application to the Current Generation of Antimalarial Drugs

July 31, 2013 - 15:27 -- Open Access
Author(s): 
Katherine Kay, Ian M. Hastings
Reference: 
PLoS Comput Biol 9(7): e1003151
MalariaWorld

Mechanism-based pharmacokinetic-pharmacodynamic (PK/PD) modelling is the standard computational technique for simulating drug treatment of infectious diseases with the potential to enhance our understanding of drug treatment outcomes, drug deployment strategies, and dosing regimens.

Medical Treatment: 

A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria among children in western Kenya

July 23, 2013 - 16:44 -- Open Access
Author(s): 
Agarwal A, McMorrow M, Onyango P, Otieno K, Odero C, Williamson J, Kariuki S, Kachur SP, Slutsker L, Desai M
Reference: 
Malaria Journal 2013, 12:254 (19 July 2013)
MalariaWorld

The efficacy of AL and dihydroartemisinin-piperaquine (DP) were evaluated for the treatment of uncomplicated malaria in children aged six to 59 months in western Kenya.

Country: 

Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia

July 22, 2013 - 17:55 -- Open Access
Author(s): 
Schramm B, Valeh P, Guérin PJ, et al.
Reference: 
Malaria Journal 2013, 12:250 (17 July 2013)
MalariaWorld

Safety surveillance of widely used artemisinin-based combination therapy (ACT) is essential, but tolerability data in the over five years age group are largely anecdotal.

Country: 

Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority

July 22, 2013 - 17:51 -- Open Access
Author(s): 
Schramm B, Valeh P, Guérin PJ, et al.
Reference: 
Malaria Journal 2013, 12:251 (17 July 2013)
MalariaWorld

These results were confirmed by observed proportion of patients cured at day 42 on the per-protocol population. Parasite clearance was 100% (ASAQ) and 99.3% (AL) on day 3. The probability to remain free of re-infection was 0.55 [95% CI: 0.46-0.63] (ASAQ) and 0.66 [0.57-0.73] (AL) (p?=?0.017).

Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients

July 17, 2013 - 12:32 -- Open Access
Author(s): 
Staehli Hodel EM, Guidi M, Zanolari B, Mercier T, Duong S, Kabanywanyi AM, Ariey F, Buclin T, Beck H, Decosterd LA, Olliaro P, Genton B, Csajka C
Reference: 
Malaria Journal 2013, 12:235 (10 July 2013)
MalariaWorld

The marked variability in the disposition of different forms of ACT remained largely unexplained by the available covariates.

Changing the malaria treatment protocol policy in Timor-Leste: an examination of context, process, and actors' involvement

May 22, 2013 - 15:15 -- Open Access
Author(s): 
João S Martins, Anthony B Zwi, Karen Hobday, Fernando Bonaparte and Paul M Kelly
Reference: 
Health Research Policy and Systems 2013, 11:16
MalariaWorld

This paper examines the challenges and opportunities identified during this period of treatment protocol change.

Pages

Subscribe to RSS - artemether-lumefantrine